Activation of p38 mitogen-activated protein kinase contributes to the early cardiodepressant action of tumor necrosis factor

被引:46
作者
Bellahcene, Mohamed
Jacquet, Sebastien
Cao, Xue B.
Tanno, Masaya
Haworth, Robert S.
Layland, Joanne
Kabir, Alamgir M.
Gaestel, Matthias
Davis, Roger J.
Flavell, Richard A.
Shah, Ajay M.
Avkiran, Metin
Marber, Michael S. [1 ]
机构
[1] Kings Coll London, Rayne Inst, Div Cardiovasc, St Thomas Hosp, London SE1 7EH, England
[2] Kings Coll London, Div Cardiovasc, Kings Coll Hosp, London WC2R 2LS, England
[3] Hannover Med Sch, Inst Biochem, D-3000 Hannover, Germany
[4] Univ Massachusetts, Howard Hughes Med Inst, Worcester, MA 01605 USA
[5] Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA
[6] Yale Univ, Sch Med, New Haven, CT USA
基金
英国惠康基金; 英国医学研究理事会;
关键词
D O I
10.1016/j.jacc.2006.02.072
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES The purpose of this study was to determine whether p38 mitogen-activated protein kinase (p38-MAPK) contributes to tumor necrosis factor-alpha (TNF alpha)-induced contractile depression. BACKGROUND Tumor necrosis factor has both beneficial and detrimental consequences that may result from the activation of different downstream pathways. Tumor necrosis factor activates p38-MAPK, a stress-responsive kinase implicated in contractile depression and cardiac injury. METHODS In isolated hearts from mice lacking the p38-MAPK activator, MAPK kinase 3 (MKK3), perfused at constant coronary pressure or flow, we measured the left ventricular developed pressure (LVDP) and the relationship between end-diastolic volume and LVDP in the presence and absence of 10 ng/ml TNF alpha. RESULTS Within 15 min at constant pressure, TNF alpha significantly reduced LVDP and coronary flow in outbred and mkk3(+/+) mice. This early negative inotropic effect was associated with a marked phosphorylation of both p38-MAPK and its indirect substrate, HSP27. In hearts lacking MKK3, TNF alpha failed to activate p38-MAPK or to cause significant contractile dysfunction. The actions of TNF alpha were similarly attenuated in MAPK-activated protein kinase 2 (MK2)-deficient hearts, which have a marked reduction in myocardial p38-MAPK protein content, and by the p38-MAPK catalytic site inhibitor SB203580 (1 mu mol/l). Under conditions of constant coronary flow, the p38-MAPK activation and contractile depression induced by TNF alpha, though attenuated, remained sensitive to the absence of MKK3 or the presence of SB203580. The role of p38-MAPK in TNF alpha-induced contractile depression was confirmed in isolated murine cardiac myocytes exposed to SB203580 or lacking MKK3. CONCLUSIONS Tumor necrosis factor activates p38-MAPK in the intact heart and in isolated cardiac myocytes through MKK3. This activation likely contributes to the early cardiodepressant action of TNF alpha.
引用
收藏
页码:545 / 555
页数:11
相关论文
共 35 条
[1]  
ARBUSTINI E, 1991, AM J PATHOL, V139, P709
[2]   Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats [J].
Bozkurt, B ;
Kribbs, SB ;
Clubb, FJ ;
Michael, LH ;
Didenko, VV ;
Hornsby, PJ ;
Seta, Y ;
Oral, H ;
Spinale, FG ;
Mann, DL .
CIRCULATION, 1998, 97 (14) :1382-1391
[3]   Acute p38 MAPK activation decreases force development in ventricular myocytes [J].
Chen, Y ;
Rajashree, R ;
Liu, QH ;
Hofmann, P .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2003, 285 (06) :H2578-H2586
[4]   Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial [J].
Chung, ES ;
Packer, M ;
Lo, KH ;
Fasanmade, AA ;
Willerson, JT .
CIRCULATION, 2003, 107 (25) :3133-3140
[5]   Effects of tumour necrosis factor-α on left ventricular function in the rat isolated perfused heart:: possible mechanisms for a decline in cardiac function [J].
Edmunds, NJ ;
Lal, H ;
Woodward, B .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (01) :189-196
[6]   Inhibitors of protein kinase signaling pathways - Emerging therapies for cardiovascular disease [J].
Force, T ;
Kuida, K ;
Namchuk, M ;
Parang, K ;
Kyriakis, JM .
CIRCULATION, 2004, 109 (10) :1196-1205
[7]   An efficient proteomics method to identify the cellular targets of protein kinase inhibitors [J].
Godl, K ;
Wissing, J ;
Kurtenbach, A ;
Habenberger, P ;
Blencke, S ;
Gutbrod, H ;
Salassidis, K ;
Stein-Gerlach, M ;
Missio, A ;
Cotten, M ;
Daub, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (26) :15434-15439
[8]   Inhibition of p38 MAPK activity falls to attenuate contractile dysfunction in a mouse model of low-flow ischemia [J].
Gorog, DA ;
Tanno, M ;
Cao, XB ;
Bellahcene, M ;
Bassi, R ;
Kabir, AMN ;
Dighe, K ;
Quinlan, RA ;
Marber, MS .
CARDIOVASCULAR RESEARCH, 2004, 61 (01) :123-131
[9]   Varying susceptibility to myocardial infarction among C57BL/6 mice of different genetic background [J].
Gorog, DA ;
Tanno, M ;
Kabir, AMN ;
Kanaganayagam, GS ;
Bassi, R ;
Fisher, SG ;
Marber, MS .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2003, 35 (06) :705-708